Subsequent platinum based re-treatment of platinum-resistant ovarian cancer: 7 cases review
의약학 > 내과학
( Junghyun Kim ) , ( Jina Yun ) , ( Ah Reum Chun ) , ( Se Hun Kim ) , ( Se Hyung Kim ) , ( Seong Kyu Park ) , ( Dae Sik Hong )
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 288(총1쪽)
42846726.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Patients who relapse within 6 months after completion of therapy are thought to be “platinum-resistant"(Pt-R) and felt to have a worse prognosis. Currently, Single agent such as topotecan, liposomal doxorubicin, vinorelbine, docetaxel and gemcitabine is used as second line setting for patients with Pt-R ovarian cancer. But, some articles have been reported that patients who have Pt-R ovarian cancer may still benefit from re-treatment with platinum compounds after an interval of treatment with nonplatinum agents. The purpose of our study was to review our experience with subsequent platinum based re-treatment in women with Pt-R ovarian cancer. We studied seven patients who had relapsed within six months of their recent exposure to platinum. They were treated with platinum based combination with topotecan, irinotecan, or docetaxel. The median age was 52 years, six patients was received paclitaxel and carboplatin combination chemotherapy prior to re treatment with platinum compounds. They received a median number of six cycles as first line chemotherapy. Two patients achieved complete respons (CR) and 5 had stable disease(SD). The median time to progression(TTP) of 1st line treatment was 8.5 months (95% CI 7.8-9.3) and the median platinum free interval was 4.6 months. All of them had good performance status(ECOG 0) before 2nd line treatment. Four patients received docetaxel-carboplatin and 3 had topotecan/irinotecan-cisplatin combination regimen. A median number of 6 cycles as re treatment with platinum compounds was received. One patient achieved CR, one patient achieved partial response, while 5 patients achieved SD. The median TTP for these seven patients after re-treatment with platinum compounds was 7.3 months (95% CI 5.1-9.4). Four patients had progressive disease and received further salvage therapy with another regimen. The median overall survival from the time deemed to be Pt-R is 22.8 months (95% CI 18.8-26.8). Our small retrospective series suggest that the Pt-R category is still less clear. Patients who have been deemed Pt-R may still benefit from subsequent platinum based re-treatment.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.